New quarterly report expected Apr 27, 2026. Report will refresh after results.
A
Alexandria Real Estate Equities, Inc.
ARE · Real Estate
Q4 FY2025
Earning ended Dec 31, 2025Report generated Mar 15, 2026
Irreplaceable Dirt, Rented With Twelve Billion Dollars of Debt
Most investors see Alexandria's moat as protection against occupancy loss — but the moat governs which tenants stay, not whether those tenants survive. A landlord with the world's stickiest buildings can still watch its income statement unravel when tenants don't defect to competitors, they simply go dark after running out of venture capital.
Flowly Score
Apr 16 Close
-58%$47.95
Fair Value
$20.00
32
Weakat $47.95
Business Strength6/10
The moat is real — irreplaceable zip codes, genuine switching costs, and a three-decade institutional playbook — but the VC platform governance conflict and the emerging AI wet-lab demand question are legitimate durability challenges that don't get enough airtime. This is a good business in an uncomfortable moment, not a great business in all weather.
Financial Resilience4/10
OCF is genuine and substantial, and the twelve-year average debt maturity is a real structural advantage — but an Altman Z near distress territory and net debt more than double the equity market cap mean resilience is entirely conditional on cap rates staying elevated and refinancing windows staying open. The cash engine is strong; the capital structure is not.
Growth & Trajectory3/10
Revenue went negative in 2025 for the first time in years, occupancy is guided lower through most of 2026, and management's recovery timeline — two to three years for core markets — assumes a biotech funding inflection that is not yet visible in venture data or IPO windows. The trajectory is deteriorating before it stabilizes.
Valuation3/10at $48.41
The EV/EBITDA multiple has expanded dramatically while fundamentals contracted — that's the market paying more for less, which is the signature of hope-based pricing rather than earnings-based pricing. Only the optimistic DCF scenario approaches current price, and it requires a biotech recovery, pipeline lease-up, and stable cap rates to all materialize simultaneously.
Risk3/10
Extreme financial leverage sits on top of a tenant base whose solvency depends on capital markets, creating a structure where even a modest miss on lease-up velocity cascades into equity impairment — the moat protects against tenant defection to competitors, but not against tenant bankruptcy, and that distinction is doing a lot of painful work right now.
Alexandria owns something genuinely scarce — the physical infrastructure underlying the world's most productive biotech clusters — and that asset quality is not in dispute. The problem is the price being paid for that asset quality relative to what the business is actually earning today. With ROIC negative in 2025, the development pipeline generating impairments rather than returns, and a biotech funding environment management itself describes as a five-year bear market, the current multiple demands a recovery scenario that hasn't started yet. The interaction of asset quality and leverage is the core tension: the assets are exceptional but the balance sheet means the equity is essentially a call option on a biotech cycle inflection. The trajectory is toward a trough before any recovery. Management is projecting occupancy declines through most of 2026, free rent requirements remain elevated on new leases, and the $2.9 billion disposition program — while operationally disciplined — is itself a signal that the company is shrinking to safety rather than growing through adversity. The more interesting long-term question is structural: AI-driven drug discovery is quietly shifting what a cutting-edge biotech company actually needs in its facilities. If computational approaches continue displacing empirical wet-lab work, demand for the specific square footage Alexandria built its empire on could face a secular ceiling that pure cycle recovery analysis doesn't capture. The single biggest risk is not vacancy — it's the leverage structure meeting a world where cap rates rise and biotech demand takes longer to recover than the three-year timeline management is projecting. With net debt exceeding twice the equity market cap, a 5% compression in asset values or a 12-18 month delay in lease commencements has an asymmetric downside impact on equity. The twelve-year average debt maturity buys time, but it doesn't eliminate the binary quality of the outcome set — and the Altman Z score is telling a story the IRR projections are not.